ScreenerHero

NERVMinerva Neurosciences, Inc.

NAS · US · Healthcare · Biotechnology · minervaneurosciences.com
4.840USD+1.04%Mkt Cap: 231.10M $P/E: —

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candi…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap231.10M $
Enterprise Value225.18M $
Revenue (TTM)—
Gross Profit-15.54M $
Net Income (TTM)-293.42M $
Revenue/Share—
Last Price4.840 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees7
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS6033802058
Valuation
P/E (Trailing)—
P/E (Forward)-11.40
PEG—
EV/EBITDA-6.41
EV/Revenue—
P/S—
P/B-1.06
EPS (TTM)-35.97
EPS (Forward)-0.42
52W Range
1.93028% of range12.46
52W High12.46 USD
52W Low1.930 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE208.47%
ROA-299.51%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-13.51M $
CapEx (TTM)—
FCF Margin—
FCF Yield-5.62%
Net Debt-15.27M $
Net Debt/EBITDA0.43
Balance Sheet
Debt/Equity—
Current Ratio20.14
Quick Ratio19.02
Book Value/Sh-4.5160 USD
Cash/Share1.576 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:8
Split DateJun 21, 2022
Analyst Consensus
Rating2.0 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)10.33 USD
Upside (mean)+113.5%
Target Range7.000 USD – 14.00 USD
$7.000+113.5% to mean$14.00
# Analysts3
Ownership
Shares Out.47.75M
Float34.32M
Insiders3.26%
Institutions93.29%
Short Interest
Short Ratio13.8d
Short % Float5.43%
Short % Out.5.18%
Shares Short2.45M
Short (prev mo.)1.90M
Technical
SMA 504.449 (+8.8%)
SMA 2005.028 (-3.7%)
Beta-0.11
S&P 52W Chg18.16%
Avg Vol (30d)158.24K
Avg Vol (10d)358.42K
Technical Indicators
RSI (14)58.1
MACD0.0303
MACD Signal-0.0574
MACD Hist.+0.0876
BB Upper4.845 USD
BB Middle4.277 USD
BB Lower3.710 USD
BB Width26.53%
ATR (14)0.3985 USD
Vol Ratio (20d)0.72x